Anti-MMP9 [2C3]

Expression of MMP9 has been identified in individual studies as prognostic biomarkers in established and locally advanced colorectal cancer.

Contributors

Inventor Institute
Ayham Alnabulsi Vertebrate Antibodies Limited
Cat. #: 151621
Tool sub type: Primary antibody
Unit size: 100 ug
Research Fields: Cancer;Cell biology;Genetics;Tissue-specific biology
Application: IHC ; IF ; IP ; WB
Target: Human matrix metalloproteinase 9 (MMP-9)
Reactivity: Human
Clone: 2C3
Host: Mouse
Class: Monoclonal
Product description: Matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix (ECM) in normal physiological processes as well as in disease processes. Tissue inhibitors of metalloproteinases (TIMPs) are the main physiological regulators of the MMPs. The TIMPs are secreted proteins that complex with individual MMPs and regulate the activity of specific MMPs. Together, the MMPs and TIMPs form a complex biological system strictly controlling degradation of ECM. The MMPs and TIMPs have a significant role in facilitating tumour invasion and metastasis. Expression of MMP9 has been identified in individual studies as prognostic biomarkers in established and locally advanced colorectal cancer.
Conjugation: Unconjugated
Isotype: IgG1 kappa
Immunogen: Ovalbumin-conjugated synthetic peptide; KLGLGADVAQVT
Myeloma used: P3X63Ag8.653
Target background: Matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix (ECM) in normal physiological processes as well as in disease processes. Tissue inhibitors of metalloproteinases (TIMPs) are the main physiological regulators of the MMPs. The TIMPs are secreted proteins that complex with individual MMPs and regulate the activity of specific MMPs. Together, the MMPs and TIMPs form a complex biological system strictly controlling degradation of ECM. The MMPs and TIMPs have a significant role in facilitating tumour invasion and metastasis. Expression of MMP9 has been identified in individual studies as prognostic biomarkers in established and locally advanced colorectal cancer.
Format: Liquid
Concentration: 0.9-1.1 mg/ml
Storage buffer: PBS with 0.02% azide
Storage conditions: -15° C to -25° C
Shipping conditions: Dry ice
References:

Sreekanth et al. 2011. Oncogene. 30(28):3139-52. PMID: 21317920.

Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer.

Jeffery et al. 2009. Histopathology. 54(7):820-8. PMID: 19635101.

The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers.

Lyall et al. 2006. Clin Cancer Res. 12(4):1184-91. PMID: 16489072.

Profiling markers of prognosis in colorectal cancer.

Curran et al. 2004. Clin Cancer Res. 10(24):8229-34. PMID: 15623598.

Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers.

Murray et al. 1998. Gut. 43(6):791-7. PMID: 9824606.

Matrix metalloproteinases and their inhibitors in gastric cancer.

Duncan et al. 1998. Eur J Biochem. 258(1):37-43. PMID: 9851689.

Human matrix metalloproteinase-9: activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form.

Murray et al. 1998. J Pathol. 185(3):256-61. PMID: 9771478.

Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer.

Images

View Gallery

Related Tools for Antibodies

Cat. # Tool Name
151030 Anti-Progesterone [11P14] Key Info View Tool
151025 Anti-Vascular endothelium [10] Key Info View Tool
151028 Anti-Cytochrome P450 2C2, 2B1/2 [h7] Key Info View Tool
151029 Anti-HSVICP8 [11E2] Key Info View Tool
151033 Anti-HSVUL42 [13C9] Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.